Formycon Believes Itself Among Frontrunners For Mammoth Keytruda Opportunity

German Firm Distances Comparisons With Saturated Humira Development Pool

On the back of early success with its biosimilar to Lucentis (ranibizumab), Formycon has looked further into the future and divulged details on the set-to-be competitive race to develop a biosimilar to Merck & Co’s €10bn ($10.9bn) PD-1 inhibitor Keytruda (pembrolizumab).

Shutterstock

Germany-based pure-play biosimilars developer Formycon believes it will see “eight to ten competitors max” in the race to develop a biosimilar to Merck & Co’s €10bn ($10.9bn) PD-1 inhibitor Keytruda (pembrolizumab), in contrast to the more saturated development pool for Humira (adalimumab), ahead of plans to kick off clinical trials for its FYB206 pembrolizumab biosimilar candidate at the end of this year or early in 2025.

Meanwhile, Formycon’s management told the recent J.P. Morgan Annual Healthcare Conference, held last week, “from competitive intelligence, we see that...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.